报价延迟最少15分钟:2026/04/03 12:52 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
35.31 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.14/0.56
|
|
企业价值
1.56B
|
| 资产负债 |
|
每股账面净值
1.41
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
272.30M
|
|
每股收益
2.77
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx. |
